An interventional study of CO2 in HPV-Related Cervical Carcinoma, Low-Grade Squamous Intraepithelial Lesions and HPV Infection, sponsored by First Affiliated Hospital of Wenzhou Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by First Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Treatment
Among 26 studies in Squamous Intraepithelial Lesions with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Squamous Intraepithelial Lesions · China.
Among the 26 studies in Squamous Intraepithelial Lesions with a site in China, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 with no phase, reaches primary completion later than 1 of the 17 other live ones, and was the 13th registered.
103 studies on the registry are indexed under Squamous Intraepithelial Lesions; 35 are open to participants now.
Browse Squamous Intraepithelial Lesions studies →17 of the 26 studies in Squamous Intraepithelial Lesions with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Newish Biotech (Wuxi) Co., Ltd. · Sites in China
Newish Biotech (Wuxi) Co., Ltd. · Sites in China
Fujian Maternity and Child Health Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 22 Squamous Intraepithelial Lesions studies recruiting now, 10 (45%) set no upper age limit and 11 (50%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 40 is below the median of 74 across 72 interventional studies indexed under Squamous Intraepithelial Lesions.
Median enrollment 153 across the 14 interventional studies, 1,000 across the 12 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 83 studies on the registry; 57 are open to participants now.
First Affiliated Hospital of Wenzhou Medical University has 1 study filed under Squamous Intraepithelial Lesions — fewer than ten, so there is no comparison to draw.
3 of the studies in Squamous Intraepithelial Lesions with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07306247Second Affiliated Hospital, Zhejiang University, School of MedicineMulticenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection | 2027-01 |
| NCT07175662Newish Biotech (Wuxi) Co., Ltd.Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL | 2027-05-30 |
| NCT07712692Newish Biotech (Wuxi) Co., Ltd.Evaluation of NWRD09 for HPV-16 Related Cervical HSIL | 2027-06-30 |
Among the 26 studies in Squamous Intraepithelial Lesions with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-RCT clinical trial comparing 5-ALA photodynamic therapy and CO2 laser for persistent high-risk HPV-related low-grade cervical lesions.
This non-randomized controlled trial aims to compare the effectiveness of two treatments, 5-aminolevulinic acid (5-ALA) photodynamic therapy and CO2 laser, for women with persistent low-grade cervical lesions associated with high-risk HPV infection lasting more than one year. The study's primary objective is to assess which treatment option yields better results. Participants in both groups will undergo specific therapeutic procedures, including 5-ALA photodynamic therapy or CO2 laser treatment. The study will analyze and compare the effects of these therapies on the regression or elimination of cervical lesions, offering valuable insights into the management of persistent low-grade cervical lesions among high-risk HPV-infected women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PDT involves cervical gel application and 25-minute laser light exposure. The procedure is repeated three times.
Procedure: CO2
CO2 laser therapy ablates cervical lesions with a depth of 7-10mm and a width of 3-5mm in a single session.
Procedure: CO2
CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
Regression of Cervical Lesions.
Measure the rate of regression in cervical lesions after three PDT sessions.
Time frame: Assessed at 6 months after the last PDT session.
Adverse Events.
Monitor and document any adverse events or complications related to CO2 laser treatment.
Time frame: Evaluated at 6 months after the CO2 laser treatment.
Plan to share: No
Ran from Sep 2023 to primary completion in Aug 2024, 10 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Intraepithelial Lesions →
First Affiliated Hospital of Wenzhou Medical University